<DOC>
	<DOCNO>NCT02544061</DOCNO>
	<brief_summary>The purpose study determine safety tolerability NM-IL-12 relative standard care ( SOC ; control ) subject open surgical wound .</brief_summary>
	<brief_title>NM-IL-12 ( rHuIL-12 ) Subjects With Open Surgical Wounds</brief_title>
	<detailed_description>This phase IIa open-label , randomize study compare safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) NM-IL-12 ( rHuIL-12 ) standard care subject open surgical wound follow colostomy takedown allow heal secondary intention .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Wound Infection</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>Scheduled undergo colostomy reversal midline wound close stoma site ( wound ) keep open heal secondary intention time operation expect close 4 6 week ( per judgment investigator ) . Able receive dose study drug within 2436 hour postoperatively demonstrate stable vital sign without unresolved major organ failure/dysfunction require critical care/monitoring least 24 hour prior receive study drug . Agree use accept highly effective method birth control ( define one result low failure rate ( i.e. , &lt; 1 % per year use consistently correctly ) continue 3 month follow receipt study drug : 1 . Sexual abstinence ( male female ) , 2 . Vasectomized partner ( female ) , 3 . Condom spermicide ( male ) combination another nonhormonal barrier method ( females 4 . Females hormonal birth control medication least 3 year without complication . Agree use accept highly effective method birth control ( define one result low failure rate ( i.e. , &lt; 1 % per year use consistently correctly ) : 1 . Sexual abstinence ( male female ) , Vasectomized partner ( female ) , 2 . Condom spermicide ( male ) combination another nonhormonal barrier method ( female ) , must agree use least 3 month follow receive study drug . 3 . Females hormonal birth control medication least 3 year without complication . Surgically sterile ( uterus bilateral tubal ligation ) postmenopausal ( menstrual period minimum 1 year ) ( female ) . A negative serum pregnancy test time enrollment study woman childbearing potential . Laboratory value white blood cell ( WBCs ) , neutrophils , lymphocytes platelet prior study drug administration Day 1 show : 1 . WBCs &gt; 3500 cells/µL , 2 . Neutrophils &gt; 2000 cells/µL , 3 . Lymphocytes &gt; 1000 cells/µL , 4 . Platelets &gt; 140,000 /µL . All clinical chemistry coagulation laboratory value enrollment must either within reference range consider clinically significant investigator sponsor . Hematological laboratory value outside reference range must report upper limit normal report clinically significant . Concurrent infection unremovable prosthetic material ( e.g. , permanent cardiac pacemaker battery pack , joint replacement prosthesis ) . Undergoing significant major plan concomitant surgical procedure hysterectomy receive antibiotic therapy within week ( 7 day ) prior date surgery perioperative antibiotic therapy . Preoperative evaluation suggest intraabdominal process might preclude full closure skin secondary intention . Treatment ( e.g. , chemotherapy , radiation ) cancer last 3 month . Concomitant use systemic steroid hormone , i.e . &gt; 10 mg/day prednisone equivalent . Concomitant use immunosuppressive immunomodulatory drug . History Crohn 's disease Ulcerative colitis . Known history drug alcohol abuse within past year . A positive screening urine toxicology also exclude patient study . Medical , social psychosocial factor , opinion investigator , could impact safety compliance study procedure . Preoperative prothrombin time ( PT ) , ALT , AST , creatinine &gt; 1.5 time upper limit normal . Lactating female . Postsurgical life expectancy ≤ 60 day , investigator sponsor 's opinion . Refusal accept medically indicate blood product . Participation within 30 day start ( dose ) study experimental drug device study , currently participate study administration investigational drug device within 60 day anticipate . Presence prosthetic cardiac valve . Known medical history ( carrier disease ) human immunodeficiency virus ( HIV ) , Hepatitis A , Hepatitis B , Hepatitis C , diseases know autoimmune origin . Known medical history tuberculosis liver cirrhosis . Current prior treatment growth factor hyperbaric therapy last 30 day precede study day 1 . History sensitivity study medication , component thereof , history drug allergy , opinion investigator medical/research monitor , contraindicate participation . Uncontrolled intercurrent illness , include , limited , ongoing serious active infection ( include eligible surgical wound ) , symptomatic congestive heart failure , unstable angina pectoris , serious cardiac arrhythmia , metastatic cancer , chronic obstructive pulmonary disease ( COPD ; ( use home oxygen therapy ) . Insulinrequiring diabetes . BMI &gt; 40 . Any condition , opinion investigator , would confound interfere evaluation safety study drug , prevent compliance study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>